Glucagon Receptor: In-Depth Analysis of Its Role in Peptide Research
Abstract: The glucagon receptor (GCGR), a class B G-protein-coupled receptor, is pivotal in peptide research for regulating glucose homeostasis via glucagon signaling. GCGR-targeted peptides, such as dual agonists (e.g., cotadutide), demonstrate enhanced efficacy in diabetes and obesity, driving a 12.3% CAGR in the peptide therapeutics market (2023–2030). Leading brands (Novo Nordisk, Eli Lilly) dominate with FDA-approved GLP-1/glucagon analogs, while emerging manufacturers emphasize purity (>98% by HPLC) and stability. Key technical advantages include prolonged half-life via fatty acid acylation; limitations involve immunogenicity risks. Product comparisons highlight receptor selectivity, bioavailability, and cold-chain logistics (2–8°C). Industry trends prioritize multi-agonist peptides, with 45% of pipeline candidates targeting GCGR. Selection criteria demand certified GMP facilities, batch-specific COAs, and validated bioactivity assays.